127 related articles for article (PubMed ID: 2443363)
1. The prognostic value of response to the first cycle of chemotherapy in small cell lung cancer. Results of a multicenter German trial.
Wolf M; Havemann K; Holle R; Harms V; Drings P; Hans K; Dombrowski H; Victor N
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1197-205. PubMed ID: 2443363
[TBL] [Abstract][Full Text] [Related]
2. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
Havemann K; Wolf M; Holle R; Gropp C; Drings P; Manke HG; Hans K; Schroeder M; Heim M; Victor N
Cancer; 1987 Mar; 59(6):1072-82. PubMed ID: 3028596
[TBL] [Abstract][Full Text] [Related]
3. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
[TBL] [Abstract][Full Text] [Related]
4. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Osterlind K; Hansen M; Hirsch FR; Dombernowsky P; Sörenson S; Pedersen AG; Hansen HH
Ann Oncol; 1991 Jan; 2(1):41-6. PubMed ID: 1848996
[TBL] [Abstract][Full Text] [Related]
7. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
[TBL] [Abstract][Full Text] [Related]
8. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy and radiotherapy in small cell carcinoma of the lung].
Yoshida S; Ogata T; Homma T; Kikuchi K; Masuda H; Matsuoka T; Sugiyama K; Noguchi Y; Yoneda S; Fukuda T
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2331-6. PubMed ID: 3015041
[TBL] [Abstract][Full Text] [Related]
10. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer.
Everson LK; Jett JR; O'Fallon JR; Krook JE; Dalton RJ; Mailliard JA; Tschetter LK; Cullinan SA; Gerstner JB; Morton RF
Am J Clin Oncol; 1989 Aug; 12(4):339-44. PubMed ID: 2547304
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification.
Broder LE; Sridhar KS; Selawry OS; Charyulu KN; Rao RK; Saldana MJ; Donnelly EJ; Raub WA
Am J Clin Oncol; 1994 Dec; 17(6):527-37. PubMed ID: 7977175
[TBL] [Abstract][Full Text] [Related]
12. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
13. [3 multicenter phase II studies of the treatment of small cell bronchogenic carcinoma (incl. AIO studies BI + BII)].
Liesenfeld A; Havemann K; Gropp C; Seifert W; Thomas C; Drings P; Mahnke HG; Westerhausen M; Wellens W; Konrad RM
Onkologie; 1984 Jun; 7(3):145-51. PubMed ID: 6087231
[TBL] [Abstract][Full Text] [Related]
14. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
Bleehen NM; Girling DJ; Machin D; Stephens RJ
Br J Cancer; 1993 Dec; 68(6):1150-6. PubMed ID: 8260367
[TBL] [Abstract][Full Text] [Related]
15. [Randomized systemic chemotherapy using two or three drug combination for small cell lung cancer (SCLC)].
Eguchi K; Shimizu E; Shinkai T; Tominaga K; Saijo N; Shimabukuro Z; Shibuya M; Niitani H
Gan No Rinsho; 1984 Feb; 30(2):115-21. PubMed ID: 6323783
[TBL] [Abstract][Full Text] [Related]
16. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung.
Osterlind K; Sörenson S; Hansen HH; Dombernowsky P; Hirsch FR; Hansen M; Rørth M
Cancer Res; 1983 Dec; 43(12 Pt 1):6085-9. PubMed ID: 6315227
[TBL] [Abstract][Full Text] [Related]
17. Sequential chemotherapy in good-prognosis patients with small-cell lung cancer.
Twelves CJ; Goldman J; Ash CM; Souhami RL; Harper PG; Spiro SG; Geddes D; Tobias JS
Cancer Chemother Pharmacol; 1991; 28(2):139-41. PubMed ID: 1647892
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
Gridelli C; Contegiacomo A; Lauria R; Gentile M; Airoma G; De Placido S; Perrone F; Ferrante G; Bianco AR
Tumori; 1991 Dec; 77(6):506-10. PubMed ID: 1666468
[TBL] [Abstract][Full Text] [Related]
19. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.
Evans WK; Feld R; Murray N; Willan A; Coy P; Osoba D; Shepherd FA; Clark DA; Levitt M; MacDonald A
Ann Intern Med; 1987 Oct; 107(4):451-8. PubMed ID: 2820289
[TBL] [Abstract][Full Text] [Related]
20. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
Bleehen NM; Girling DJ; Machin D; Stephens RJ
Br J Cancer; 1993 Dec; 68(6):1157-66. PubMed ID: 7505104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
